CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings

CareDx, Inc. (Nasdaq: CDNA) —The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that it will be showcasing the breadth of its specialized digital solutions and the latest advancements in its cellular therapy and transplant monitoring pipeline at the 2024 Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR^®, being held February 21-25 in San Antonio, Texas.

“Cellular transplant centers are recognizing the value of our digital and patient monitoring solutions, and we look forward to sharing our latest advancements as we work to expand our presence in this dynamic ecosystem,” said Kashif Rathore, Chief of Patient and Digital Solutions at CareDx.

CareDx Digital Product Theatre

CareDx will be showcasing its broad portfolio of digital health solutions that address needs in the cellular transplant and therapy ecosystem including workflow management, regulatory reporting, medication management, and remote patient monitoring. Product solution areas include:

• Ottr® Cellular: Designed as a workflow management solution for hematopoietic cellular transplant and cellular therapy centers.
• MedActionPlan PRO®: Designed to improve medication adherence and simplify medication regimens.
• AlloHome® remote patient monitoring: Designed for patient engagement and timely interventions.
• AlloCare® patient mobile health app: Helps patients track personal health metrics and test results and manage their complex medication regimens.

CareDx is advancing its product pipeline with new data for AlloHeme™ and AlloCell™ that can help monitor treatment response after allogeneic hematopoietic stem cell transplantation and allogeneic cell therapy, respectively.

Data being presented:

• Oral Presentation: TScan’s TSC-100 and TSC-101, TCR-T Cell Therapies That Target Residual Recipient Cells after Reduced Intensity Conditioning Transplantation, Induce Complete Donor Chimerism with Favorable Prognosis: Early Results of a Phase 1 Trial. In this TScan study AlloHeme is used as an exploratory marker in subjects with mismatched HA1 and HA2 minor HLA antigens, and respective controls.
• Poster 555: Micro-Chimerism Detected By Highly Sensitive AlloHeme™ Solution Is Associated with Treatment Response and Relapse after Allogeneic Stem Cell Transplantation. Presenting interim data from the prospective multi-center ACROBAT study that supports the clinical utility of ultra-sensitive chimerism monitoring for detection of early relapse post allogeneic HCT.
• Poster 299: Analytical Validation of AlloCell cfDNA - a Highly Sensitive, Precise, and Accurate Cell-Free DNA-Based Test for Allogeneic Cell Therapy Monitoring.
• Poster 645: Regimen Adherence Insights after Allogeneic Hematopoietic Stem Cell Transplantation from a Central Specialty Pharmacy.

“We’re thrilled to present interim study findings from the ACROBAT study, revealing AlloHeme is able to more accurately measure chimerism levels with much higher sensitivity than the current methods for patients with AML, ALL, or MDS undergoing allogeneic hematopoietic cell therapy,” said Dr. Stefan Ciurea of the University of California, Irvine. “The ACROBAT study aims to assess the role of AlloHeme for early relapse detection, potentially paving the way for improved therapeutic interventions to prevent disease relapse post-transplant and improved treatment outcomes.”

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit:www.CareDx.com.

Forward Looking Statements

This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with AlloHeme™, AlloCell™, CareDx’s digital health solutions, and CareDx’s presentation of its latest pipeline advancements in cellular transplant and therapy monitoring at the 2024 Tandem Meetings (the “Tandem Presentation”). These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of AlloHeme, AlloCell, its digital health solutions or its Tandem Presentation; risks that the Tandem Meetings and the data to be presented may not follow the agenda as stated in this press release; risks that the findings in the studies supporting the data may be inaccurate, general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed by CareDx with the SEC on February 27, 2023, the quarterly report on Form 10-Q for the quarter ended March 31, 2023 filed by CareDx with the SEC on May 10, 2023, the quarterly report on Form 10-Q for the quarter ended June 30, 2023 filed by CareDx with the SEC on August 8, 2023, the quarterly report on Form 10-Q for the quarter ended September 30, 2023 filed by CareDx with the SEC on November 8, 2023, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240221575484/en/